Cytotoxic Agents Can Cure Cancer, but Can Also Kill Cancer Patients

The objective of this article is to rectify cytotoxic cancer therapies which are inadequate to cause escalating cancer mortality, and to promote cell differentiation agent (CDA) formulations as perfect cancer drugs to reduce cancer mortality. Cancer mortality is the ultimate judgment of the success of cancer therapy. Cancer mortality keeps on increasing, which is an indication that cancer therapies currently in practice are apparently wrong. To effectively solve cancer, we must find out how the problem of cancer evolves. Cancer evolves due to wound unhealing because of the collapse of chemo-surveillance, which is the nature’s creation of allosteric regulation on abnormal methylation enzymes (MEs) to ensure perfection of wound healing. Progenitor stem cells (PSCs) are the cells involved in wound healing. The inability to heal wound allows PSCs to evolve into CSCs and then to progress to faster growing cancer cells (CCs). Solution of CSCs is essential to achieve life time remission. CSCs are protected by drug resistance, anti-apoptosis and DNA repair mechanisms. Thus, CSCs are unresponsive to cytotoxic therapies. Cytotoxic therapies must rely on the restoration of chemo-surveillance to subdue surviving CSCs to achieve cancer therapy. Only early stage cancer patients whose chemo-surveillance have not yet been fatally damaged can benefit from cytotoxic therapies. CDA formulations are the best drugs for the elimination of CSCs, which can come to the rescue of advanced cancer patients whose chemo-surveillance have been fatally damaged. The approval of CDA formulations is blocked by cancer establishments because these drugs cannot make tumor to disappear. The requirement of tumor shrinkage must be removed for the approval of CDA formulations to save advanced cancer patients.